This company has been marked as potentially delisted and may not be actively trading.

Viveon Health Acquisition (VHAQ) Competitors

VHAQ vs. SGMT, ARCT, NVCT, PLYX, and ALXO

Should you be buying Viveon Health Acquisition stock or one of its competitors? The main competitors of Viveon Health Acquisition include Sagimet Biosciences (SGMT), Arcturus Therapeutics (ARCT), Nuvectis Pharma (NVCT), Polaryx Therapeutics (PLYX), and ALX Oncology (ALXO). These companies are all part of the "pharmaceutical products" industry.

How does Viveon Health Acquisition compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

: 87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 22.1% of Viveon Health Acquisition shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 75.3% of Viveon Health Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Viveon Health Acquisition's return on equity of 0.00% beat Sagimet Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Sagimet Biosciences N/A -40.85% -38.63%
Viveon Health Acquisition N/A N/A N/A
: Sagimet Biosciences has a beta of 3.6, meaning that its stock price is 260% more volatile than the S&P 500. Comparatively, Viveon Health Acquisition has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
: In the previous week, Sagimet Biosciences had 15 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 15 mentions for Sagimet Biosciences and 0 mentions for Viveon Health Acquisition. Viveon Health Acquisition's average media sentiment score of 0.00 beat Sagimet Biosciences' score of -0.13 indicating that Viveon Health Acquisition is being referred to more favorably in the news media.
Company Overall Sentiment
Sagimet Biosciences Neutral
Viveon Health Acquisition Neutral
: Sagimet Biosciences currently has a consensus price target of $28.63, indicating a potential upside of 270.79%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than Viveon Health Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagimet Biosciences
1 Sell rating(s)
2 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.67
Viveon Health Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: Viveon Health Acquisition has lower revenue, but higher earnings than Sagimet Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sagimet Biosciences $2M 125.76 -$51.04M -$1.57 N/A
Viveon Health Acquisition N/A N/A -$610K N/A N/A

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-40.85%	-38.63%
Viveon Health Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Sagimet Biosciences	Neutral
Viveon Health Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67
Viveon Health Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	125.76	-$51.04M	-$1.57	N/A
Viveon Health Acquisition	N/A	N/A	-$610K	N/A	N/A

Summary

Sagimet Biosciences beats Viveon Health Acquisition on 7 of the 12 factors compared between the two stocks.

How does Viveon Health Acquisition compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

: Arcturus Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Viveon Health Acquisition has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500.
: Viveon Health Acquisition has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -80.19%. Viveon Health Acquisition's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Arcturus Therapeutics -80.19% -29.13% -22.03%
Viveon Health Acquisition N/A N/A N/A
: In the previous week, Arcturus Therapeutics had 2 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 2 mentions for Arcturus Therapeutics and 0 mentions for Viveon Health Acquisition. Arcturus Therapeutics' average media sentiment score of 0.19 beat Viveon Health Acquisition's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Arcturus Therapeutics Neutral
Viveon Health Acquisition Neutral
: 94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 22.1% of Viveon Health Acquisition shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 75.3% of Viveon Health Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Viveon Health Acquisition has lower revenue, but higher earnings than Arcturus Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arcturus Therapeutics $82.03M 2.91 -$65.78M -$2.38 N/A
Viveon Health Acquisition N/A N/A -$610K N/A N/A
: Arcturus Therapeutics currently has a consensus price target of $29.50, indicating a potential upside of 250.77%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Viveon Health Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics
1 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.69
Viveon Health Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-80.19%	-29.13%	-22.03%
Viveon Health Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Arcturus Therapeutics	Neutral
Viveon Health Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.91	-$65.78M	-$2.38	N/A
Viveon Health Acquisition	N/A	N/A	-$610K	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Viveon Health Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Arcturus Therapeutics beats Viveon Health Acquisition on 9 of the 14 factors compared between the two stocks.

How does Viveon Health Acquisition compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

: Nuvectis Pharma has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Viveon Health Acquisition has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500.
: Viveon Health Acquisition's return on equity of 0.00% beat Nuvectis Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Nuvectis Pharma N/A -143.91% -92.79%
Viveon Health Acquisition N/A N/A N/A
: In the previous week, Nuvectis Pharma had 5 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 5 mentions for Nuvectis Pharma and 0 mentions for Viveon Health Acquisition. Nuvectis Pharma's average media sentiment score of 0.03 beat Viveon Health Acquisition's score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the media.
Company Overall Sentiment
Nuvectis Pharma Neutral
Viveon Health Acquisition Neutral
: 96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 22.1% of Viveon Health Acquisition shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 75.3% of Viveon Health Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvectis Pharma N/A N/A -$26.44M -$1.32 N/A
Viveon Health Acquisition N/A N/A -$610K N/A N/A
: Nuvectis Pharma presently has a consensus price target of $10.00, suggesting a potential upside of 2.99%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Nuvectis Pharma is more favorable than Viveon Health Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectis Pharma
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Viveon Health Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-143.91%	-92.79%
Viveon Health Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Nuvectis Pharma	Neutral
Viveon Health Acquisition	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.32	N/A
Viveon Health Acquisition	N/A	N/A	-$610K	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Viveon Health Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Nuvectis Pharma beats Viveon Health Acquisition on 6 of the 11 factors compared between the two stocks.

How does Viveon Health Acquisition compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Viveon Health Acquisition (NYSE:VHAQ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

: In the previous week, Polaryx Therapeutics had 1 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 1 mentions for Polaryx Therapeutics and 0 mentions for Viveon Health Acquisition. Polaryx Therapeutics' average media sentiment score of 0.00 equaled Viveon Health Acquisition'saverage media sentiment score.
Company Overall Sentiment
Polaryx Therapeutics Neutral
Viveon Health Acquisition Neutral
: Company Net Margins Return on Equity Return on Assets
Polaryx Therapeutics N/A N/A N/A
Viveon Health Acquisition N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polaryx Therapeutics N/A N/A N/A N/A N/A
Viveon Health Acquisition N/A N/A -$610K N/A N/A
: Polaryx Therapeutics presently has a consensus price target of $10.00, suggesting a potential upside of 120.26%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Polaryx Therapeutics is more favorable than Viveon Health Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polaryx Therapeutics
1 Sell rating(s)
0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Viveon Health Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 22.1% of Viveon Health Acquisition shares are owned by institutional investors. 75.3% of Viveon Health Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Viveon Health Acquisition	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Viveon Health Acquisition	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Viveon Health Acquisition	N/A	N/A	-$610K	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Viveon Health Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Polaryx Therapeutics beats Viveon Health Acquisition on 4 of the 6 factors compared between the two stocks.

How does Viveon Health Acquisition compare to ALX Oncology?

Viveon Health Acquisition (NYSE:VHAQ) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

: In the previous week, ALX Oncology had 4 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 4 mentions for ALX Oncology and 0 mentions for Viveon Health Acquisition. Viveon Health Acquisition's average media sentiment score of 0.00 beat ALX Oncology's score of -0.26 indicating that Viveon Health Acquisition is being referred to more favorably in the media.
Company Overall Sentiment
Viveon Health Acquisition Neutral
ALX Oncology Neutral
: Viveon Health Acquisition's return on equity of 0.00% beat ALX Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Viveon Health Acquisition N/A N/A N/A
ALX Oncology N/A -182.01% -113.63%
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viveon Health Acquisition N/A N/A -$610K N/A N/A
ALX Oncology N/A N/A -$101.69M -$1.90 N/A
: Viveon Health Acquisition has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
: ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 138.34%. Given ALX Oncology's stronger consensus rating and higher probable upside, analysts clearly believe ALX Oncology is more favorable than Viveon Health Acquisition.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viveon Health Acquisition
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
ALX Oncology
1 Sell rating(s)

0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
: 22.1% of Viveon Health Acquisition shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 75.3% of Viveon Health Acquisition shares are held by company insiders. Comparatively, 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Overall Sentiment
Viveon Health Acquisition	Neutral
ALX Oncology	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Viveon Health Acquisition	N/A	N/A	N/A
ALX Oncology	N/A	-182.01%	-113.63%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viveon Health Acquisition	N/A	N/A	-$610K	N/A	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.90	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viveon Health Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

ALX Oncology beats Viveon Health Acquisition on 6 of the 11 factors compared between the two stocks.

Get Viveon Health Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VHAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VHAQ vs. The Competition

Export

Metric	Viveon Health Acquisition	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$62.26M	$883.41M	$6.25B	$22.85B
Dividend Yield	N/A	4.84%	2.74%	4.06%
P/E Ratio	N/A	1.71	29.25	28.55
Price / Sales	N/A	119.23	504.68	24.24
Price / Cash	N/A	20.07	43.30	25.18
Price / Book	N/A	7.60	9.67	5.37
Net Income	-$610K	-$4.80M	$3.55B	$1.07B

Viveon Health Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VHAQ Viveon Health Acquisition	N/A	$11.00 flat	N/A	N/A	$62.26M	N/A	N/A	2
SGMT Sagimet Biosciences	2.1042 of 5 stars	$7.61 -5.2%	$26.00 +241.7%	N/A	$247.97M	N/A	N/A	8	Trending News Analyst Forecast Analyst Revision
ARCT Arcturus Therapeutics	2.4937 of 5 stars	$8.63 +0.1%	$29.50 +241.8%	N/A	$245.01M	$82.03M	N/A	180	Positive News Upcoming Earnings
NVCT Nuvectis Pharma	0.5271 of 5 stars	$8.54 -0.2%	$10.00 +17.1%	N/A	$236.84M	N/A	N/A	8	News Coverage Earnings Report
PLYX Polaryx Therapeutics	N/A	$4.88 -7.0%	$10.00 +104.9%	N/A	$229.51M	N/A	N/A	11	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:VHAQ) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viveon Health Acquisition (VHAQ) Competitors

VHAQ vs. SGMT, ARCT, NVCT, PLYX, and ALXO

How does Viveon Health Acquisition compare to Sagimet Biosciences?

Summary

How does Viveon Health Acquisition compare to Arcturus Therapeutics?

Summary

How does Viveon Health Acquisition compare to Nuvectis Pharma?

Summary

How does Viveon Health Acquisition compare to Polaryx Therapeutics?

Summary

How does Viveon Health Acquisition compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VHAQ vs. The Competition

Viveon Health Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viveon Health Acquisition (VHAQ) Competitors

VHAQ vs. SGMT, ARCT, NVCT, PLYX, and ALXO

How does Viveon Health Acquisition compare to Sagimet Biosciences?

Summary

How does Viveon Health Acquisition compare to Arcturus Therapeutics?

Summary

How does Viveon Health Acquisition compare to Nuvectis Pharma?

Summary

How does Viveon Health Acquisition compare to Polaryx Therapeutics?

Summary

How does Viveon Health Acquisition compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VHAQ vs. The Competition

Viveon Health Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools